Patents by Inventor Sally Freeman

Sally Freeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors
    Patent number: 10570157
    Abstract: Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 ? activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: February 25, 2020
    Assignee: THE UNIVERSITY OF MANCHESTER
    Inventors: David Brough, Stuart McRae Allan, Sally Freeman, Alex George Baldwin
  • CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20180215772
    Abstract: Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 ? activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Inventors: David Brough, Stuart McRae Allan, Sally Freeman, Alex George Baldwin
  • Pharmaceutical composition
    Patent number: 6900181
    Abstract: The present invention concerns analogues of M6P for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, together with methods for doing same.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: May 31, 2005
    Assignee: Renovo Limited
    Inventors: Mark W. J. Ferguson, Sarah G. Jones, Sally Freeman
  • Drug targeting
    Patent number: 6881748
    Abstract: A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclization reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: April 19, 2005
    Assignee: The Victoria University of Manchester
    Inventors: Sally Freeman, Mohammed Jaffor, Ian Stratford
  • Pharmaceutical composition
    Publication number: 20040072763
    Abstract: The present invention concerns analogues of M6P for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, together with methods for doing same.
    Type: Application
    Filed: March 18, 2003
    Publication date: April 15, 2004
    Applicant: RENOVO LIMITED
    Inventors: Mark W.J. Ferguson, Sarah G. Jones, Sally Freeman
  • Pharmaceutical composition
    Patent number: 6566339
    Abstract: The present invention concerns analogues of M6P for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, together with methods for doing same.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: May 20, 2003
    Assignee: Renovo Limited
    Inventors: Mark William James Ferguson, Sarah Glenys Moore, Sally Freeman
  • Pharmaceutical composition
    Patent number: 6140307
    Abstract: The present invention concerns analogues of mannose-6-phosphate for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, and methods for doing same.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: October 31, 2000
    Assignee: The Victoria University of Manchester
    Inventors: Mark William James Ferguson, Sarah Glenys Moore, Sally Freeman
  • Pancratistatin prodrug
    Patent number: 5529989
    Abstract: Pancratistatin has been selected for pre-clinical development but is sparingly soluble in water. A disodium phosphate derivative has been synthesized which is water soluble and is bioequivalent thereof. The critical step in the synthesis of the phenolic phosphate was phosphorylation of 1,2,3,4-tetraacetoxy-pancratistatin with dibenzyloxy(N,N-diisopropylamido)phosphine.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: June 25, 1996
    Assignee: Arizona Board of Regents acting on behalf of Arizona State University
    Inventors: George R. Pettit, Sally Freeman